Advances in the clinical development of oncolytic viruses.

ABSTRACT:

Objectives

Oncolytic viruses (OVs) are natural or recombinant viruses that selectively infect and kill cancer cells without harming normal cells. This review aimed to explore some ongoing and completed clinical studies on OVs, in China and worldwide, to depict a comprehensive landscape of OV clinical trials, and summarize the existing evidence on safety and effectiveness of oncolytic therapy against tumors.

Methods

Used the Center for Drug Evaluation of China National Medical Products Administration (NMPA), Chinese Clinical Trial Registry (ChiCTR), International Clinical Trials Registry Platform, ClinicalTrials.gov website, China National Knowledge Infrastructure (CNKI), and PubMed.

Results

As of October 1, 2021, 408 clinical trials on 31 OV products have been conduct

SUBMITTER: Li K 

PROVIDER: S-EPMC9274612 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature